Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 9, 2011, Pages 3005-3021

  Kubota, Katsumi ^a   Kurebayashi, Hirotaka ^a   Miyachi, Hirotaka ^a   Tobe, Masanori ^a   Onishi, Masako ^a   Isobe, Yoshiaki ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Anti histamine; Anti inflammatory; Dibenzoxazepine; H1 receptor antagonist; Pyrimidine 2,4(1H,3H) dione

Indexed keywords

2 [5 [3 [4 (1,3 DIMETHYL 2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL) 1,4 DIAZEPAN 1 YL]PROPYL] 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPIN 7 YL] 2 METHYLPROPANOIC ACID; 2 [5 [3 [4 (1,3 DIMETHYL 2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL) 1,4 DIAZEPAN 1 YL]PROPYL] 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPIN 7 YL]ACETIC ACID; 2 [5 [3 [4 (1,3 DIMETHYL 2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL) 1,4 DIAZEPAN 1 YL]PROPYL] 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPIN 7 YL]PROPANOIC ACID; 2 [5 [3 [4 (1,3 DIMETHYL 2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL)PIPERAZIN 1 YL]PROPYL] 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPIN 7 YL]ACETIC ACID; 5 [3 (BENZYLOXY)PROPYL] 3 BROMO 10,11 DIHYDRO 5H DIBENZO[B,F]AZEPINE; 5 [3 [4 (1,3 DIMETHYL 2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL) 1,4 DIAZEPAN 1 YL]PROPYL] 10,11 DIHYDRO 5H DIBENZO[B,F]AZEPINE 3 CARBOXYLIC ACID; 5 [3 [4 (1,3 DIMETHYL 2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL) 1,4 DIAZEPAN 1 YL]PROPYL] 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPINE 3 CARBOXYLIC ACID; 5 [3 [4 (1,3 DIMETHYL 2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL) 1,4 DIAZEPAN 1 YL]PROPYL] 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPINE 7 CARBOXYLIC ACID; 5 [3 [4 (1,3 DIMETHYL 2,6 DIOXO 1,2,3,6 TETRAHYDROPYRIMIDIN 4 YL)PIPERAZIN 1 YL]PROPYL] 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPINE 7 CARBOXYLIC ACID; AMITRIPTYLINE; ETHYL 4 (2 BROMOBENZYLOXY) 3 NITROBENZOATE; ETHYL 5 (3 HYDROXYPROPYL) 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPINE 3 CARBOXYLATE; ETHYL 5 (3 HYDROXYPROPYL) 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPINE 7 CARBOXYLATE; ETHYL 5 ALLYL 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPINE 3 CARBOXYLATE; ETHYL 5 ALLYL 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPINE 7 CARBOXYLATE; ETHYL 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPINE 7 CARBOXYLATE; IMIPRAMINE; METHYL 2 (5 ALLYL 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPIN 7 YL) 2 METHYLPROPANOATE; METHYL 2 (5 ALLYL 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPIN 7 YL)ACETATE; METHYL 2 (5 ALLYL 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPIN 7 YL)PROPANOATE; METHYL 2 [5 (3 HYDROXYPROPYL) 10,11 DIHYDRO 5H DIBENZO[B,F]AZEPIN 3 YL] 2 METHYLPROPANOATE; METHYL 2 [5 (3 HYDROXYPROPYL) 10,11 DIHYDRO 5H DIBENZO[B,F]AZEPIN 3 YL]ACETATE; METHYL 2 [5 (3 HYDROXYPROPYL) 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPIN 7 YL] 2 METHYLPROPANOATE; METHYL 2 [5 (3 HYDROXYPROPYL) 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPIN 7 YL]ACETATE; METHYL 2 [5 (3 HYDROXYPROPYL) 5,11 DIHYDRODIBENZO[B,E][1,4]OXAZEPIN 7 YL]PROPANOATE; METHYL 5 (3 HYDROXYPROPYL) 10,11 DIHYDRO 5H DIBENZO[B,F]AZEPINE 3 CARBOXYLATE; OLOPATADINE; TAK 427; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CARBON NUCLEAR MAGNETIC RESONANCE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYCLIZATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; TEMPERATURE DEPENDENCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AZEPINES; CACO-2 CELLS; CARBOXYLIC ACIDS; CELL MEMBRANE PERMEABILITY; CYCLIZATION; HISTAMINE H1 ANTAGONISTS; HUMANS; MICE; OXAZEPINES; PROTEIN BINDING; PYRIMIDINES; RATS; RECEPTORS, HISTAMINE H1; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS; RATTUS;

EID: 79955475433     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.03.003     Document Type: Article

References (41)

1. K. Baba, and K. Nakae Prog. Med. 28 2008 2001
2. A. Nakamura, T. Asai, H. Yoshida, K. Baba, and K. Nakae J. Otolaryngol. Jpn 105 2002 215
3. P.H. Howarth, S. Wilson, L. Lau, and K. Rajakulasingam Clin. Exp. Allergy 21 1991 3
4. P. Bradding, I.H. Feather, S. Wilson, P.G. Bardin, C.H. Heusser, S.T. Holgate, and P.H. Howarth J. Immunol. 151 1993 3853
5. P. Christodoulopoulos, L. Cameron, S. Durham, and Q. Hamid J. Allergy Clin. Immunol. 105 2000 211
6. F. Horak Allergy 57 2002 25
7. S.T. Holgate, G.W. Canonica, F.E.R. Simons, M. Taglialatela, M. Tharp, H. Timmerman, and K. Yanai Clin. Exp. Allergy 33 2003 1305
8. R. Morphy, and Z. Rankovic J. Med. Chem. 48 2005 6523
9. M. Gyoten, H. Nagaya, S. Fukuda, Y. Ashida, and Y. Kawano Chem. Pharm. Bull. 51 2003 122
10. S. Fukuda, K. Midoro, T. Kamei, M. Gyoten, Y. Kawano, Y. Ashida, and H. Nagaya J. Pharmacol. Exp. Ther. 303 2002 1283
11. S. Fukuda, K. Midoro, M. Gyoten, Y. Kawano, Y. Ashida, T. Nabe, S. Kohno, and H. Nagaya Eur. J. Pharmacol. 476 2003 239
12. K. Kubota, H. Kurebayashi, H. Miyachi, M. Tobe, M. Onishi, and Y. Isobe Bioorg. Med. Chem. Lett. 19 2009 2766
13. K. Ohmori, K. Hasegawa, T. Tamura, K. Miyake, M. Matsubara, S. Masaki, A. Karasawa, N. Urayama, K. Horikoshi, J. Kajita, M. Hasegawa, K. Taniguchi, T. Komada, and Y. Kawamoto Arzneimittelforschung 54 2004 809
14. A. Markham, and A. Wagstaff Drugs 55 1998 269
15. A. Graul Drugs Future 21 1996 1017
16. K. Simpson, and B. Jarvis Drugs 59 2000 301
17. L.Y. Harry, and S. Francis J. Med. Chem. 1964 609
18. L. Gyermek Int. Rev. Neurobiol. 9 1966 95
19. E. Oshima, S. Otaki, H. Sato, T. Kumazawa, H. Obase, A. Ishii, H. Ishii, K. Ohmori, and N. Hirayama J. Med. Chem. 35 1992 2074
20. H.L. Yale, B. Beer, J. Plusces, and E.R. Spitzmiller J. Med. Chem. 13 1970 713
21. Minute synthetic procedure and scheme was described in Section 2 and Supplementary data.
22. C. Ferenc, and H. Sándor J. Prakt. Chem. 399 1997 587
23. L. Sunwoo, A.B. Neil, and F.H. John J. Am. Chem. Soc. 123 2001 8410
24. R. Steven, and C. Trevor J. Org. Chem. 44 1979 3760
25. A.B. Neil, and F.H. John J. Org. Chem. 67 2002 541
26. S. Carsten, and W. Wolfgang Synthesis 2002 655
27. P. Paolo, T. Gabriella, B. Alberto, A.M. Robert, M. Roberto, C. Carla, S. Patricia, and V. Mario Bioorg. Med. Chem. Lett. 9 1999 1783
28. Y. Inoue, M. Isobe, and H. Hayashi J. Pharmacol. Sci. 91 2003 71
29. T. Kumazawa, E. Oshima, H. Harakawa, H. Sato, H. Obase, Y. Oiji, A. Ishii, H. Ishii, and K. Ohmori Chem. Pharm. Bull. 39 1991 2729
30. S. Thangapandian, N. Krishnamoorthy, S. John, S. Sakkiah, P. Lazar, Y. Lee, and K.W. Lee Bull. Korean Chem. Soc. 31 2010 52
31. S. Ram, A.K. Saxena, P.C. Jain, and G.K. Patnaik Ind. J. Chem. 23B 1984 1261
32. M.L. Kapsenberg, H.M. Jansen, J.D. Bos, and E.A. Wierenga Curr. Opin.Immunol 4 1992 788
33. I. Iwamoto, S. Tomoe, H. Tomioka, K. Takatsu, and S.J. Yoshida Leukocyte Biol 52 1992 572
34. M. Gaga, A.J. Frew, V.A. Varney, and A.B. Kay J. Immunol 147 1991 816
35. K. Sawada, H. Nagai, Y. Basaki, H. Yamaya, K. Ikizawa, M. Watanabe, M. Kojima, N. Matsuura, and M. Kiniwa Clin. Exp. Allergy 27 1997 225
36. M. Togawa, M. Kiniwa, and H. Nagai Life Sci. 69 2001 699
37. 1A, and potassium channel HERG.
38. A. Gupta, M. Gillard, B. Christophe, P. Chatelain, R. Massingham, and M. Hammarlund-Udenaes Br. J. Pharmacol. 151 2007 1129
39. K. Yanai, and M. Tashiro Pharmacol. Ther. 113 2007 1
40. K. Yanai, M. Tashiro, and N. Okamura Mol. Med. 41 2004 1008
41. See data in the Supplementary data.